The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them.
The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.
One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials.
The researchers discovered mutations in essentially the same genes and came to very similar conclusions with regard to the increased cancer risk.
NEW YORK (GenomeWeb) – NeoGenomics today reported a 37 percent year-over-year increase in its third quarter revenues.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.